The pharmaceutical community is intrigued by retatrutide, a new dual GIP and GLP-1 agonist that’s showing remarkable results in early research. This treatment works by replicating natural hormones to impact appetite and increase feelings of satiety, ultimately leading considerable body loss . Whi